Paper and Cover Image Published in Science in China


Paper Published in Lancet Infectious Diseases


Paper and Cover Image Published at Nature's web site











 
  Z-BioMed Inc. is a biotech company engaged in conducting innovative research and product development in the area of infectious diseases such as influenza and TB. Z-BioMed has won SBIR awards from NIH and CDC and successfully completed projects in a timely manner.

Z-BioMed has established an excellent reputation for providing high quality products, responsive and outstanding biotechnology services to customers from government agents, research universities and pharmaceutical companies.

For more information regarding Z-BioMed's products, services and collaboration opportunities, please send e-mail to: info@zbiomed.com.


Recent Publications

March 2012
Article published online in Journal of Clinical Microbiology
Genetic Diversity and Drug Susceptibility of Mycobacterium Tuberculosis Isolates from Zunyi, One of the Highest Incidence Rate Areas in China
Journal of Clinical Microbiology 2012 50(3):1043-1047.
Abstract      Full Text

February 2012
Book Chapter published online in InTech Open
Survey and Molecular Characterization of Drug-Resistant M. tuberculosis Clinical Isolates from Zunyi, Guizhou Province of China
Understanding Tuberculosis - Global Experiences and Innovative Approaches to the Diagnosis  Pere-Joan Cardona (Ed.), ISBN: 978-953-307-938-7, InTech.
Book Chapter      Book

September 2011
Article published in Chinese Journal of Zoonoses
Proteomics Comparison of XDR and MDR Microbacterium Tuberculosis
Chinese Journal of Zoonoses 2011 September; 27(9):820-824.
Abstract      Full Text

July 2011
Article published in Journal of Antimicrobial Chemotherapy
High prevalence of multidrug-resistant tuberculosis in Zunyi, Guizhou Province of China
Journal of Antimicrobial Chemotherapy 2011 July 26; doi:10.1093/jac/dkr319.
PMID: 21795258 [PubMed-in process]
Abstract      Full Text

February 2011
Article published in PLoS One
Phylogenetic Diversity and Genotypical Complexity of H9N2 Influenza A Viruses Revealed by Genomic Sequence Analysis
PLoS One 2011 Feb; 6(2): e17212. doi:10.1371/journal.pone.0017212.
PMID: 21386964 [PubMed-in process]
Abstract      Full Text

December 2010
Article published in Vet Immunol Immunopathol
Characterization of monoclonal antibodies against goat interleukin-18 and their application in the measurement of goat interleukin-18 in LPS-stimulated peripheral blood mononuclear cells by sandwich ELISA
Vet Immunol Immunopathol 2010 Dec; 138, 235-238.
PMID: 20692710 [PubMed-in process]
Abstract

June 2010
Article published in Journal of Antimicrobial Chemotherapy
RpoB gene mutation profile in rifampicin-resistant Mycobacterium tuberculosis clinical isolates from Guizhou, one of the highest-incidence-rate regions in China
Journal of Antimicrobial Chemotherapy 2010 June; 65(6), 1299-1301.
Full Text

March 2010
Article published in Basic & Clinic Medicine
Sequencing analysis on rpoB gene mutation of rifampin-resistence in Mycobacterium tuberculosis
Basic & Clinic Medicine 30(3), 268-271.
Abstract

December 2009
Article published in Science in China Ser C
Tissue and host tropism of influenza viruses: importance of quantitative analysis
Science in China Ser C-Life Sci 2009 Dec;52(12):1101-10.
PMID: 20016966 [PubMed-in process]
Abstract     Full Text

August 2009
Article published in The Lancet Infectious Diseases
Possible origin of current influenza A H1N1 viruses
Lancet Infect Dis 2009 Aug;9(8):456-7.
PMID: 19628166 [PubMed-in process]
Full Text

April 2009
Article published in Journal of Infectious Diseases
DAS181 and H5N1 Virus Infection
J Infect Dis 2009 Apr 15;199(8):1250.
PMID: 19302014 [PubMed-indexed for MEDLINE]
Full Text

February 2009
Article published in Antimicrob Agents Chemotherapy
Sialidase fusion protein as inhibitor of infection by influenza virus
Antimicrob Agents Chemother. 2009 Mar;53(3):1297.
PMID: 19234358 [PubMed-indexed for MEDLINE]
Full Text     PDF

June 2008
Article published in Journal of Antimicrobial Chemotherapy
Concerns of using sialidase fusion protein as an experimental drug to combat seasonal and pandemic influenza--author's response
Journal of Antimicrobial Chemotherapy 2008 62(2):428-429; doi:10.1093/jac/dkn220.
Full Text     

January 2008
Article published in Journal of Antimicrobial Chemotherapy
Concerns of using sialidase fusion protein as an experimental drug to combat seasonal and pandemic influenza
Journal of Antimicrobial Chemotherapy 2008 62(2):219-223; doi:10.1093/jac/dkn026.
PMID: 18238888 [PubMed-indexed for MEDLINE]     Abstract       Full Text     PDF

December 2006
Article including the cover image published online at Nature's web site: http://www.nature.com/cr/journal/v16/n12/abs/7310115a.html
Identification of key genes responsible for cytokine-induced erythroid and myeloid differentiation and switching of hematopoietic stem cells by RAGE.
Cell Research 2006 Dec;16(12):923-39.
PMID: 17146449 [PubMed-indexed for MEDLINE]    Abstract

December 2006
Corresponding Letter to the Editor of Antimicrobial Agents and Chemotherapy ( Letter to AAC 12-7-06 )
In conclusion, the statement made by Malakhov et al "In several experiments performed much later, MDCK or EAC cells were briefly treated with Vibrio cholerae sialidase and then infected with influenza virus. Influenza virus infections were decreased by 90 to 100% as a result of the sialidase treatment (6, 13, 52)" is inaccurate and needs to be corrected.

August 2006
Article Published in Investigative Ophthalmology & Visual Science
Visual response properties of retinal ganglion cells in the royal college of surgeons dystrophic rat.
Invest Ophthalmol Vis Sci. 2006 Aug;47(8):3579-85.
PMID: 16877432 [PubMed - indexed for MEDLINE]     Abstract    

July 2006
Article Published in Microbes and Infection
Signature patterns revealed by microarray analyses of mice infected with influenza virus A and Streptococcus pneumoniae.
Microbes Infect. 2006 Jul;8(8):2172-85. Epub 2006 Jun 2.
PMID: 16797204 [PubMed - indexed for MEDLINE]    Abstract


PCR Mutation Calculator

To calculate the percentage of PCR-induced mutants with different polymerases such as Taq, Pfu, Vent and Deep Vent in any PCR products, enter the target size and cycling number to the following table.

  Enter PCR target size (e.g. 200bp): 
  Enter cycling number (e.g.  30): 
         
Bio Techniques Bio Techniques


15725 Crabbs Branch Way, Rockville, MD 20855, U.S.A.
Phone: 301-258-8968  
Email: info@zbiomed.com

Home | Products | FAQs | Services | Order Info | Contact Us | Events 
Copyright © 2012 Z-BioMed Inc. All rights reserved.